
    
      Non interventional multi-centric study that will aim in evaluating the efficacy and safety of
      Fondaparinux in surgical cancer patients, identifying in parallel the most relevant and
      critical risk factors for Thromboembolism.

      It is a cohort study, recruiting cancer patients over 18 years of age, who have been
      diagnosed with cancer for over a period of one year.

      Exclusion criteria apply as well while all patients can withdraw their participation at any
      time point.
    
  